Patients who undergo transplant face an increased risk of skin cancer because of their immunosuppressed status, explained Christine Ko, MD, professor of dermatology and pathology at Yale University.
Patients who undergo transplant face an increased risk of skin cancer because of their immunosuppressed status, notably from the medicines they are on to prevent organ rejection, some of which can cause DNA mutations, explained Christine Ko, MD, professor of dermatology and pathology at Yale University.
Transcript
What factors predispose transplant patients to a higher risk of skin cancers?
So I enjoy transplant dermatology because I've been interested for a long time in skin cancer. One of the more common skin cancers they get is reported to be squamous cell carcinoma, which has been a long-standing interest of mine, initially more from the dermatopathology side. So these types of patients, some people are surprised. Some of my friends are like, “Why are you seeing transplant patients?” I reply, “Well, I just look at their skin.” The reason they're at increased risk for skin cancer is because of the immunosuppressive medicines they're on to prevent rejection of the transplanted organ. The great thing is, medicine is continuing to evolve and some of the newer immunosuppressive medicines that they're put on are not as promoting of skin cancer.
So that's great, but for example, azathioprine used to be used more, and that can directly cause mutations in our genetic code, in our DNA. And that's not good. There's a relationship also with sun exposure and sun damage; sun also being able to cause ultraviolet light–induced mutations. And so anything that can sort of add on to that is not good, and azathioprine can do that.
Cyclosporine and tacrolimus are other medicines that are used more often now, compared to azathioprine, and they're both in a class called calcineurin inhibitors. Those medicines don't directly cause DNA damage—like kind of inserting themselves into the DNA the way that azathioprine does—so that's good. But both of those also have strong immunosuppressive effects, which transplant doctors want for the sake and the patient wants too for the sake of their transplanted organ, but [they] can reduce immune surveillance, which is important for preventing skin cancer, particularly in sun-damaged skin of these patients who sometimes have very light skin and a significant amount of sun exposure from the past.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More